CHINOOK THERAPEUTICS INC's ticker is KDNY and the CUSIP is 16961L106. A total of 152 filers reported holding CHINOOK THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.03 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $31,740,875 | +60.8% | 826,155 | -10.8% | 0.23% | +67.2% |
| Q1 2023 | $19,734,445 | -18.7% | 926,155 | 0.0% | 0.14% | -16.5% |
| Q4 2022 | $24,264,124 | +41.7% | 926,155 | +6.3% | 0.16% | +35.5% |
| Q3 2022 | $17,128,000 | +12.4% | 871,155 | 0.0% | 0.12% | -3.2% |
| Q2 2022 | $15,236,000 | -21.4% | 871,155 | -26.5% | 0.12% | -5.3% |
| Q1 2022 | $19,391,000 | +7.6% | 1,185,314 | +7.3% | 0.13% | +14.8% |
| Q4 2021 | $18,021,000 | +56.5% | 1,104,902 | +22.4% | 0.12% | +47.4% |
| Q3 2021 | $11,516,000 | -6.8% | 902,537 | +3.1% | 0.08% | -8.2% |
| Q2 2021 | $12,357,000 | – | 875,124 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 5,161,888 | $119,497,707 | 24.70% |
| Saturn V Capital Management LP | 506,818 | $11,732,837 | 8.76% |
| Octagon Capital Advisors LP | 2,551,703 | $59,071,924 | 8.50% |
| Affinity Asset Advisors, LLC | 976,021 | $22,594,886 | 7.46% |
| Frazier Life Sciences Management, L.P. | 4,345,559 | $100,599,691 | 7.28% |
| Altium Capital Management LP | 305,000 | $7,060,750 | 3.92% |
| Deep Track Capital, LP | 3,000,000 | $69,450,000 | 2.85% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 319,989 | $7,407,745 | 2.07% |
| Nan Fung Group Holdings Ltd | 113,950 | $2,637,943 | 1.80% |
| Nicholas Investment Partners, LP | 972,191 | $22,506,222 | 1.71% |